The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 08, 2015

Filed:

Dec. 22, 2004
Applicants:

Takashi Nishimura, Sapporo, JP;

Masaki Yasukawa, Matsuyama, JP;

Inventors:

Takashi Nishimura, Sapporo, JP;

Masaki Yasukawa, Matsuyama, JP;

Assignee:

TELLA, INC., Tokyo, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/00 (2006.01); C12N 5/08 (2006.01); C12N 15/63 (2006.01); C07H 21/04 (2006.01); A01N 63/00 (2006.01); A61K 39/395 (2006.01); A61K 48/00 (2006.01); A61K 35/26 (2015.01); A61K 39/00 (2006.01); C12N 5/0783 (2010.01); C12N 15/85 (2006.01); C12N 5/16 (2006.01);
U.S. Cl.
CPC ...
A61K 35/26 (2013.01); A61K 39/0011 (2013.01); A61K 39/395 (2013.01); A61K 2039/5156 (2013.01); C07H 21/04 (2013.01); C12N 5/0636 (2013.01); C12N 5/16 (2013.01); C12N 15/63 (2013.01); C12N 15/85 (2013.01);
Abstract

A novel process for preparing tumor-specific T cells is disclosed. According to the invention, antitumor-active, tumor-specific T cells are prepared by transducing a TCR gene from a tumor-specific CTL into antitumor-active T cells that have been nonspecifically activated, thus enabling tumor-specific cellular immunotherapy to be carried out from even small amounts of blood. MHC class I-restricted, tumor-specific Th cells are obtained by the method, allowing for the production of cells that react with tumor cells expressing an MHC class I molecule and show a helper activity and an antitumor activity.


Find Patent Forward Citations

Loading…